11.61
Astria Therapeutics Inc Aktie (ATXS) Neueste Nachrichten
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS) - WV News
Astria Therapeutics (ATXS) Acquisition Sparks Interest in Naveni - GuruFocus
Oppenheimer downgrades Astria Therapeutics stock rating to Perform on BioCryst acquisition - Investing.com UK
Low frequency sounds good to Biocryst in $700M Astria HAE buy - BioWorld MedTech
Astria Therapeutics (ATXS) Acquisition Boosts Confidence in BioC - GuruFocus
ATXS Rating Downgraded: Jefferies Lowers Price Target | ATXS Sto - GuruFocus
BioCryst to Acquire Astria in $700M Deal - USA Herald
Covington, Sidley Guide $700M BioCryst Allergic Disease Deal - Law360
Dow Jumps Over 300 Points; Citigroup Posts Upbeat Earnings - Benzinga
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate' - Benzinga
BioCryst Pharmaceuticals, Inc. agreed to acquire Astria Therapeutics, Inc.. - MarketScreener
Shareholder Alert: The Ademi Firm investigates whether Astria Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - PR Newswire
Here’s Why Astria Therapeutics Stock (ATXS) Exploded Today - TipRanks
BioCryst to Acquire Astria Therapeutics in $700 Million Deal - Contract Pharma
BioCryst deepens rare diseases focus with $700 million deal for Astria - Reuters
Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On TuesdayAmerican Resources (NASDAQ:AREC), Albertsons Companies (NYSE:ACI) - Benzinga
ATXS Stocks Flying High: Too Late to Buy? - StocksToTrade
BioCryst To Acquire Astria Therapeutics - citybiz
ATXS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Astria Therapeutics, Inc. Is Fair to Shareholders - Business Wire
BioCryst to Acquire Astria Therapeutics for $700 Million Includi - GuruFocus
BioCryst Announces Acquisition of Astria Therapeutics (ATXS) at $13.00 Per Share - GuruFocus
BioCryst (BCRX) to Acquire Astria Therapeutics in $700M Deal - GuruFocus
BioCryst To Acquire Astria Therapeutics In $700M Deal - Stocktwits
BioCryst Pharmaceuticals To Acquire Astria Therapeutics In $700 Million Cash-and-Stock Deal - Nasdaq
BioCryst to acquire Astria Therapeutics for $700 million - Investing.com
Astria Therapeutics (ATXS) Acquired by BioCryst in $700M Deal - GuruFocus
BioCryst to buy Astria Therapeutics in $700 million deal - Yahoo Finance
BioCryst To Acquire Astria Therapeutics In $700 Mln Cash-and-Stock Deal - Nasdaq
Astria Therapeutics stock soars after BioCryst acquisition announcement, BioCryst falls By Investing.com - Investing.com Canada
BioCryst Announces Merger with Astria Therapeutics - TipRanks
BioCryst to buy Astria Therapeutics for $13 per share - MSN
Combining price and volume data for Astria Therapeutics Inc.July 2025 Final Week & Risk Managed Investment Signals - newser.com
BioCryst to acquire Astria Therapeutics, strengthening presence in HAE, transforming growth profile - MarketScreener
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile - GlobeNewswire
What to do if you’re stuck in Astria Therapeutics Inc.July 2025 PostEarnings & Weekly Market Pulse Alerts - newser.com
Can Astria Therapeutics Inc. stock maintain operating margins2025 Momentum Check & Fast Moving Stock Watchlists - newser.com
How to forecast Astria Therapeutics Inc. trends using time seriesMarket Risk Report & Real-Time Buy Signal Alerts - newser.com
Published on: 2025-10-14 01:02:46 - newser.com
BioCryst Pharmaceuticals To Acquire Astria In $700 Million Deal - Finimize
Institutional scanner results for Astria Therapeutics Inc.2025 Technical Overview & Weekly High Return Forecasts - newser.com
Is it too late to sell Astria Therapeutics Inc.Swing Trade & Expert Verified Stock Movement Alerts - newser.com
3 Biotech Stocks That Could More Than Triple if Their Trials Succeed - MSN
3 Biotech Stocks That Could More Than Triple If Their Trials Succeed - Barchart.com
Can Astria Therapeutics Inc. stock sustain institutional interest2025 Market Outlook & High Conviction Buy Zone Alerts - newser.com
Comparing Astria Therapeutics Inc. in custom built stock radars2025 Retail Activity & Verified Entry Point Signals - newser.com
Visual analytics tools that track Astria Therapeutics Inc. performanceJuly 2025 Institutional & Scalable Portfolio Growth Methods - newser.com
Tick level data insight on Astria Therapeutics Inc. volatility2025 Winners & Losers & Technical Entry and Exit Tips - newser.com
Weiss Ratings Reaffirms Sell (D-) Rating for Astria Therapeutics (NASDAQ:ATXS) - MarketBeat
H.C. Wainwright reiterates Buy rating on Astria Therapeutics stock at $20 - Investing.com Canada
Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting - Business Wire
Analyzing Astria Therapeutics Inc. with multi timeframe chartsEarnings Risk Summary & Reliable Price Breakout Signals - newser.com
How to interpret RSI for Astria Therapeutics Inc. stock2025 Investor Takeaways & Reliable Volume Spike Alerts - newser.com
Astria Therapeutics begins phase 3 long-term trial for HAE treatment - Investing.com Nigeria
Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with - PharmiWeb.com
Astria Therapeutics (ATXS) Begins Phase 3 Trial for Hereditary A - GuruFocus
Astria Therapeutics begins phase 3 long-term trial for HAE treatment By Investing.com - Investing.com South Africa
Astria Therapeutics initiates the phase 3 ORBIT-EXPANSE long-term trial of navenibart in people with hereditary angioedema - MarketScreener
Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema - Business Wire
Astria Therapeutics, Inc. $ATXS Stock Position Lifted by Farther Finance Advisors LLC - Defense World
How strong is Astria Therapeutics Inc. stock balance sheetJuly 2025 Weekly Recap & Technical Pattern Based Buy Signals - newser.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):